Novartis Reports Real World Evidence from Psoriasis patients indicating Treatment to Exceed Beyond Clear Skin and safety
Shots:
- The survey enrolled 300 (US respondents) psoriasis patients are interested in additional benefits i.e. no. of years of proven efficacy and safety with no injection site reactions in addition to clear skin
- Survey also indicated that efficacy of drug in treating multiple manifestations of psoriatic disease was also important for patients while no. of injections per dose and their frequency was less preferred in patients
- This online DCE survey is aimed to help dermatologists understand patient’s preference for five selected attributes differentiating biologic treatments from moderate-to-severe plaque psoriasis
/ article | Ref: Novartis | Image: Wall Street
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com